U.S. Trade Distributors Stock News

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

With a price-to-earnings (or "P/E") ratio of 25.2x IDEX Corporation ( NYSE:IEX ) may be sending very bearish signals at...

Key Insights Significantly high institutional ownership implies E.W. Scripps' stock price is sensitive to their trading...

JPMorgan Chase ( NYSE:JPM ) First Quarter 2025 Results Key Financial Results Revenue: US$42.0b (up 4.8% from 1Q 2024...

As every investor would know, you don't hit a homerun every time you swing. But it would be foolish to simply accept...

To the annoyance of some shareholders, ProQR Therapeutics N.V. ( NASDAQ:PRQR ) shares are down a considerable 34% in...

Key Insights Given the large stake in the stock by institutions, Liquidia's stock price might be vulnerable to their...

Did you know there are some financial metrics that can provide clues of a potential multi-bagger? In a perfect world...

When you buy and hold a stock for the long term, you definitely want it to provide a positive return. But more than...

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...

With a price-to-earnings (or "P/E") ratio of 10x Omnicom Group Inc. ( NYSE:OMC ) may be sending bullish signals at the...

Key Insights The projected fair value for GeneDx Holdings is US$140 based on 2 Stage Free Cash Flow to Equity GeneDx...

Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...

Arm Holdings (NasdaqGS:ARM) recently withdrew from pursuing an acquisition of Alphawave IP Group, a potential strategic move to fortify its AI capabilities. This decision comes as technology stocks experience a volatile week influenced by news of tariff exemptions on smartphones, computers, and chips. Despite this, Arm's 17% price rise over the week aligns with the broader market's upward trend of nearly 6%. The market also saw significant activity with tech stocks, like Intel and Palantir,...

Rocket Lab USA (NasdaqCM:RKLB) recently introduced its new STARRAY solar arrays and Frontier RF Communications Systems, showcasing the company's continuous innovation in satellite technology. The stock price rose by 12% over the last week, partly supported by these product advancements. Concurrently, the company's announcement about its selection by the U.S. Space Force for high-profile national security missions further solidifies its market position and could have contributed to the share...

Okta (NasdaqGS:OKTA) introduced its Auth for GenAI feature, aiming to enhance security for AI applications, which may have supported its 23% quarterly share price increase. In addition to this product innovation, Okta's significant earnings report highlighted improved revenues and net income, potentially boosting investor confidence. The appointment of Eric Kelleher as President and COO could underscore strategic leadership advancements, and partnerships with companies like Incode...

CyberArk Software (NasdaqGS:CYBR) launched new identity security solutions during its IMPACT 2025 Conference, including tools for AI agents and machine identities, and partnered with Accenture to enhance AI security. These developments coincide with CyberArk achieving SOC 2 Type 2 compliance. Over the last week, CyberArk's share price increased by 14%. This rise aligns with broader market gains driven by a positive market trend, as evidenced by the strong performance of major indices like the...

BioNTech (NasdaqGS:BNTX) saw its share price increase by 11%, coinciding with significant market activity and major index gains. While the company itself did not have any significant news or announcements within that week, the broader market trends, including technology stocks gaining momentum due to tariff exemptions, likely buoyed BioNTech amidst a sector-wide lift. The broader positive market sentiment, demonstrated by a 5.8% rise, provided a favorable backdrop for the company's stock...

MercadoLibre (NasdaqGS:MELI) recently announced a substantial investment increase in Brazil, aiming to expand logistics, technology, and marketing with a 48% rise in local currency spending for 2025. During the last quarter, the company experienced a 14% stock price increase, which aligns with its ambitious growth plans in Brazil and Mexico. Notably, these moves complemented broader market trends, as major indexes including the S&P 500 and Dow Jones showed significant gains driven by tech...

Palo Alto Networks (NasdaqGS:PANW) saw its share price increase by 10% over the past week, coinciding with significant corporate developments. The company's recent multiyear partnership with the National Hockey League aims to fortify cybersecurity across the league, potentially enhancing the company's market position. As the broader technology sector experienced mixed results amid relief from tariff exemptions, Palo Alto Networks' robust performance aligns with a general market uplift, which...

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on the bright side, you...

Broadcom (NasdaqGS:AVGO) recently announced a substantial share buyback program worth up to $10 billion, enhancing investor confidence. Concurrently, the company is advancing its optical interconnect solutions to support AI infrastructure, potentially bolstering its market position. In the broader market context, tech stocks experienced volatility amid news of tariff exemptions, affecting companies differently within the sector. The tech-heavy Nasdaq Composite saw various fluctuations,...

Summit Therapeutics (NasdaqGM:SMMT) recently experienced an executive shakeup with the appointment of Robert LaCaze as Chief Commercial Officer, which could have influenced its stock price increase of nearly 40% over the last quarter. LaCaze brings substantial experience in oncology, possibly strengthening market confidence in the company's growth initiatives. Additionally, the firm's collaboration with Pfizer to evaluate ivonescimab in combination with Pfizer's ADCs may have bolstered its...